https://www.selleckchem.com/pr....oducts/tj-m2010-5.ht
Planned outcomes The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48. Secondary and exploratory endpoints include safety and ophthalmologic and internal medical clinical parameters. Registration This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961) and Japan Registry of Clinical Trials (jRCTs03118021.Spinal cord injury (SCI) is involved with abnormal expression of miRNAs (miRs) whi
Like
Comment
Share
